nivolumab,ipilimumab
bms
['rcc,(-irccs),(-srcc),(-urcc)', 'cm-214']
always exciting when a quality of life abstract gets selected for oral presentation at #asco22. for rcc oral session, presented on relationship between baseline and longitudinal hrqol and long-term pfs and os outcomes in cm-214. 
Med onc at UW/SCCA/Fred Hutch focused on melanoma and RCC, interested in patient/caregiver QOL and all things immunotherapy. All opinions are my own.